Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12

Cytokine and Growth Factor Reviews

Volumn 24, Issue 1, 2013, Pages 41-49

  Singh, Anup Kumar ^a   Arya, Rakesh Kumar ^a   Trivedi, Arun Kumar ^a   Sanyal, Sabyasachi ^a   Baral, Rathindranath ^b   Dormond, Olivier ^c   Briscoe, David M ^d   Datta, Dipak ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; CXC chemokines; Metastasis; Tumor growth

Indexed keywords

AMG 487; CCX 2066; CCX 754; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CXCL11 CHEMOKINE; GUANINE NUCLEOTIDE BINDING PROTEIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STEM CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; ENDOTHELIUM CELL; HUMAN; INTRACELLULAR SIGNALING; LUNG CANCER; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SOLID TUMOR; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CXCL11; CHEMOKINE CXCL12; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR CROSS-TALK; RECEPTORS, CXCR; RECEPTORS, CXCR3; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 84874252337     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.08.007     Document Type: Short Survey

References (99)

1. Howard O.M., Ben-Baruch A., Oppenheim J.J. Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends in Biotechnology 1996, 14:46-51.
2. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
3. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. New England Journal of Medicine 1998, 338:436-445.
4. Romagnani P., Lasagni L., Annunziato F., Serio M., Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends in Immunology 2004, 25:201-209.
5. Horuk R. Chemokine receptors. Cytokine and Growth Factor Reviews 2001, 12:313-335.
6. Murphy P.M. The molecular biology of leukocyte chemoattractant receptors. Annual Review of Immunology 1994, 12:593-633.
7. Rajagopal S., Rajagopal K., Lefkowitz R.J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nature Reviews Drug Discovery 2010, 9:373-386.
8. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
9. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Letters 2008, 267:226-244.
10. Vandercappellen J., Van Damme J., Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine and Growth Factor Reviews 2011, 22:1-18.
11. Keeley E.C., Mehrad B., Strieter R.M. CXC chemokines in cancer angiogenesis and metastases. Advances in Cancer Research 2010, 106:91-111.
12. Balkwill F. Cancer and the chemokine network. Nature Reviews Cancer 2004, 4:540-550.
13. Duda D.G., Kozin S.V., Kirkpatrick N.D., Xu L., Fukumura D., Jain R.K. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clinical Cancer Research 2011, 17:2074-2080.
14. Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer and Metastasis Reviews 2010, 29:709-722.
15. Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. Journal of Experimental Medicine 2003, 197:1537-1549.
16. Caruz A., Samsom M., Alonso J.M., Alcami J., Baleux F., Virelizier J.L., et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Letters 1998, 426:271-278.
17. Nagasawa T., Tachibana K., Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Seminars in Immunology 1998, 10:179-185.
18. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
19. Aiuti A., Tavian M., Cipponi A., Ficara F., Zappone E., Hoxie J., et al. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. European Journal of Immunology 1999, 29:1823-1831.
20. + progenitors to peripheral blood. Journal of Experimental Medicine 1997, 185:111-120.
21. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:9448-9453.
22. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
23. Ratajczak M.Z., Zuba-Surma E., Kucia M., Reca R., Wojakowski W., Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006, 20:1915-1924.
24. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
25. Fulton A.M. The chemokine receptors CXCR4 and CXCR3 in cancer. Current Oncology Reports 2009, 11:125-131.
26. Holland J.D., Kochetkova M., Akekawatchai C., Dottore M., Lopez A., McColl S.R. Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Research 2006, 66:4117-4124.
27. Choi W.T., Duggineni S., Xu Y., Huang Z., An J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). Journal of Medicinal Chemistry 2012, 55:977-994.
28. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
29. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clinical and Experimental Metastasis 2008, 25:345-356.
30. Zlotnik A., Burkhardt A.M., Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nature Reviews Immunology 2011, 11:597-606.
31. Furusato B., Mohamed A., Uhlén M., Rhim J.S. CXCR4 and cancer. Pathology International 2010, 60:497-505.
32. Zagzag D., Lukyanov Y., Lan L., Ali M.A., Esencay M., Mendez O., et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Laboratory Investigation 2006, 86:1221-1232.
33. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer 2008, 8:755-768.
34. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
35. Miki J., Furusato B., Li H., Gu Y., Takahashi H., Egawa S., et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Research 2007, 67:3153-3161.
36. Salmaggi A., Boiardi A., Gelati M., Russo A., Calatozzolo C., Ciusani E., et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006, 54:850-860.
37. Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry 2005, 280:35760-35766.
38. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. Journal of Experimental Medicine 2006, 203:2201-2213.
39. Libert F., Parmentier M., Lefort A., Dumont J.E., Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Research 1990, 18:1917.
40. Libert F., Passage E., Parmentier M., Simons M.J., Vassart G., Mattei M.G. Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor. Genomics 1991, 11:225-227.
41. Broberg K., Zhang M., Strömbeck B., Isaksson M., Nilsson M., Mertens F., et al. Fusion of RDC1 with HMGA2 in lipomas as the result of chromosome aberrations involving 2q35-37 and 12q13-15. International Journal of Oncology 2002, 21:321-326.
42. Infantino S., Moepps B., Thelen M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. Journal of Immunology 2006, 176:2197-2207.
43. Berahovich R.D., Penfold M.E., Schall T.J. Nonspecific CXCR7 antibodies. Immunology Letters 2010, 133:112-114.
44. Berahovich R.D., Zabel B.A., Penfold M.E., Lewén S., Wang Y., Miao Z., et al. CXCR7 protein is not expressed on human or mouse leukocytes. Journal of Immunology 2010, 185:5130-5139.
45. D'Apuzzo M., Rolink A., Loetscher M., Hoxie J.A., Clark-Lewis I., Melchers F., et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. European Journal of Immunology 1997, 27:1788-1793.
46. Honczarenko M., Douglas R.S., Mathias C., Lee B., Ratajczak M.Z., Silberstein L.E. SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells. Blood 1999, 94:2990-2998.
47. Humpert M.L., Tzouros M., Thelen S., Bignon A., Levoye A., Arenzana-Seisdedos F., et al. Complementary methods provide evidence for the expression of CXCR7 on human B cells. Proteomics 2012, 12:1938-1948.
48. Thelen M., Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio?. Journal of Neuroimmunology 2008, 198:9-13.
49. Yoshida T., Imai T., Kakizaki M., Nishimura M., Takagi S., Yoshie O. Identification of single C motif-1/lymphotactin receptor XCR1. Journal of Biological Chemistry 1998, 273:16551-16554.
50. Chandrasekar B., Bysani S., Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. Journal of Biological Chemistry 2004, 279:3188-3196.
51. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
52. Rajagopal S., Kim J., Ahn S., Craig S., Lam C.M., Gerard N.P., et al. Beta-arrestin- but not G protein-mediated signaling by the " decoy" receptor CXCR7. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:628-632.
53. Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E., Zerwes H.G., et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS ONE 2010, 5:e9175.
54. Luker K.E., Lewin S.A., Mihalko L.A., Schmidt B.T., Winkler J.S., Coggins N.L., et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012, 10.1038/onc.2011.633.
55. Décaillot F.M., Kazmi M.A., Lin Y., Ray-Saha S., Sakmar T.P., Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. Journal of Biological Chemistry 2011, 286:32188-32197.
56. Ray P., Mihalko L.A., Coggins N.L., Moudgil P., Ehrlich A., Luker K.E., et al. Carboxy-terminus of CXCR7 regulates receptor localization and function. International Journal of Biochemistry and Cell Biology 2012, 44:669-678.
57. Canals M., Scholten D.J., de Munnik S., Han M.K., Smit M.J., Leurs R. Ubiquitination of CXCR7 controls receptor trafficking. PLoS ONE 2012, 7:e34192.
58. Maishi N., Ohga N., Hida Y., Akiyama K., Kitayama K., Osawa T., et al. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathology International 2012, 62:309-317.
59. Hernandez L., Magalhaes M.A., Coniglio S.J., Condeelis J.S., Segall J.E. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Research 2011, 13:R128.
60. Wang J., Shiozawa Y., Wang Y., Jung Y., Pienta K.J., Mehra R., et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. Journal of Biological Chemistry 2008, 283:4283-4294.
61. Singh R.K., Lokeshwar B.L. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Research 2011, 71:3268-3277.
62. Grymula K., Tarnowski M., Wysoczynski M., Drukala J., Barr F.G., Ratajczak J., et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. International Journal of Cancer 2010, 127:2554-2568.
63. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. Journal of Experimental Medicine 1996, 184:963-969.
64. Trentin L., Agostini C., Facco M., Piazza F., Perin A., Siviero M., et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation 1999, 104:115-121.
65. Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. Journal of Experimental Medicine 1998, 187:2009-2021.
66. Hancock W.W., Lu B., Gao W., Csizmadia V., Faia K., King J.A., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. Journal of Experimental Medicine 2000, 192:1515-1520.
67. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. Journal of Experimental Medicine 1998, 187:129-134.
68. Reinders M.E., Sho M., Izawa A., Wang P., Mukhopadhyay D., Koss K.E., et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. Journal of Clinical Investigation 2003, 112:1655-1665.
69. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P., et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564.
70. Datta D., Flaxenburg J.A., Laxmanan S., Geehan C., Grimm M., Waaga-Gasser A.M., et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Research 2006, 66:9509-9518.
71. Datta D., Contreras A.G., Grimm M., Waaga-Gasser A.M., Briscoe D.M., Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. Journal of the American Society of Nephrology 2008, 19:2437-2446.
72. Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., Strieter R.M. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. Journal of Immunology 2004, 173:6234-6240.
73. Wenzel J., Bekisch B., Uerlich M., Haller O., Bieber T., Tüting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. American Journal of Clinical Pathology 2005, 124:37-48.
74. + T lymphocytes but not inhibition of angiogenesis. Journal of Immunotherapy 2005, 28:343-351.
75. Chu Y., Yang X., Xu W., Wang Y., Guo Q., Xiong S. In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunology, Immunotherapy 2007, 56:1539-1549.
76. Luster A.D., Greenberg S.M., Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. Journal of Experimental Medicine 1995, 182:219-231.
77. Ma X., Norsworthy K., Kundu N., Rodgers W.H., Gimotty P.A., Goloubeva O., et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Molecular Cancer Therapeutics 2009, 8:490-498.
78. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Research 2006, 66:7701-7707.
79. Kawada K., Sonoshita M., Sakashita H., Takabayashi A., Yamaoka Y., Manabe T., et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Research 2004, 64:4010-4017.
80. Furuya M., Yoneyama T., Miyagi E., Tanaka R., Nagahama K., Miyagi Y., et al. Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis. Gynecologic Oncology 2011, 122:648-655.
81. Zipin-Roitman A., Meshel T., Sagi-Assif O., Shalmon B., Avivi C., Pfeffer R.M., et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Research 2007, 67:3396-3405.
82. Lo B.K., Yu M., Zloty D., Cowan B., Shapiro J., McElwee K.J. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. American Journal of Pathology 2010, 176:2435-2446.
83. Yu Y., Merlino G. Roles for aberrant CXCR3 signaling in basal cell carcinoma: a case for dual activity. American Journal of Pathology 2010, 176:2088-2091.
84. Busillo J.M., Benovic J.L. Regulation of CXCR4 signaling. Biochimica et Biophysica Acta 2007, 1768:952-963.
85. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical Cancer Research 2010, 16:2927-2931.
86. Boldajipour B., Mahabaleshwar H., Kardash E., Reichman-Fried M., Blaser H., Minina S., et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132:463-473.
87. Dambly-Chaudière C., Cubedo N., Ghysen A. Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Developmental Biology 2007, 7:23.
88. Petrai I., Rombouts K., Lasagni L., Annunziato F., Cosmi L., Romanelli R.G., et al. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. International Journal of Biochemistry and Cell Biology 2008, 40:1764-1774.
89. Datta D., Banerjee P., Gasser M., Waaga-Gasser A.M., Pal S. CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. Journal of Biological Chemistry 2010, 285:36842-36848.
90. Goldsmith Z.G., Dhanasekaran D.N. G protein regulation of MAPK networks. Oncogene 2007, 26:3122-3142.
91. Mellado M., Rodríguez-Frade J.M., Mañes S., Martínez A.C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annual Review of Immunology 2001, 19:397-421.
92. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. Journal of Pathology 2008, 215:211-213.
93. Hattermann K., Held-Feindt J., Lucius R., Müerköster S.S., Penfold M.E., Schall T.J., et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Research 2010, 70:3299-3308.
94. Ray P., Lewin S.A., Mihalko L.A., Lesher-Perez S.C., Takayama S., Luker K.E., et al. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. Biochemical Journal 2012, 442:433-442.
95. Hawkins O.E., Richmond A. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Research 2012, 14:103.
96. Wu Q., Dhir R., Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Molecular Cancer 2012, 11:3.
97. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
98. Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 1971, 285:1182-1186.
99. De Clercq E. The bicyclam AMD3100 story. Nature Reviews Drug Discovery 2003, 2:581-587.